| 摘要 |
The present invention provides a combination product comprising a first a gent that inhibits the biological activity of hCAP18/LL-37; and a second age nt that inhibits the biological activity of an EGF receptor, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-a cceptable adjuvant, diluent or carrier. In a preferred embodiment, the agent (s) alter the transcription, translation and/or binding properties of hCAP18 /LL-37 and/or an EGF receptor. Preferably, the agent(s) are selected from th e group consisting of short interfering RNA (siRNA) molecules, antisense oli gonucleotides and compounds with binding affinity for hCAP18/LL-37 and/or EG F receptors. The invention further provides methods for inhibiting the proli feration and/or metastasis of cancer cells in a patient, and pharmaceutical compositions for use in the treatment of cancer.
|
